SCL Science Inc, formerly InnoTherapy Inc, is a Korea-based company principally engaged in the research, development, manufacture, export and sale of medical hemostatic agents. The main developed products include medical hemostats and sealants with biomimetic technology. In addition, the Company is engaged in the bio-logistics business.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
30/26/30	₩2,620.00	-6.26%	2,50,495
29/26/29	₩2,795.00	-2.78%	3,88,861
28/26/28	₩2,875.00	+5.70%	3,19,585
23/26/23	₩2,720.00	+11.25%	4,77,149
22/26/22	₩2,445.00	+0.82%	1,27,444

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 30/09/2026			5-day change	1st Jan Change
2,620.00 ^KRW	-6.26%		+7.16%	+13.91%

14/08	SCL Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
15/05	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	8.91TCr 6.58Cr 5.79Cr 5.49Cr 4.96Cr 9.34Cr 630.81Cr 9.46Cr 66Cr 25Cr 322.48Cr 25Cr 24Cr 1.03TCr	P/E 2024	-16x	P/E 2025	-19.2x
Enterprise Value	11TCr 8.24Cr 7.26Cr 6.88Cr 6.21Cr 12Cr 790.31Cr 12Cr 82Cr 32Cr 404.02Cr 31Cr 30Cr 1.3TCr	EV / Sales 2024	13.3x	EV / Sales 2025	4.57x
Free-Float	45.72%	Yield 2024 *	-	Yield 2025	-

14/08	SCL Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
15/05	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
23/03	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
23/12	SCL Science Inc. agreed to acquire Bio-logistics business in Honam region of Seoul Clinical Laboratories for KRW 4.3 billion.	CI
14/11	SCL Science Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11/25/11	Scl Science to acquire 1.6 billion won worth of shares and majority stake in Pentamedix Co Ltd	RE
11/25/11	SCL Science Inc. agreed to acquire 60.31% stake in PentaMedix Co., Ltd. for KRW 1.6 billion.	CI
14/25/14	Scl Science wins 530 million won order	RE
14/25/14	SCL Science Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
28/25/28	SCL Science Inc. agreed to acquire Bio-logistics business in Yeongnam region of Seoul Clinical Laboratories from Seoul Clinical Laboratories for KRW 5.0 billion.	CI
15/25/15	SCL Science Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/25/31	SCL Science Inc. completed the acquisition of SCL Healthcare Co., Ltd.	CI
20/25/20	SCL Science Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

1 day	-6.26%
1 week	+7.16%
Current month	+13.91%
1 month	+18.82%
3 months	+58.79%
6 months	+17.23%
Current year	+13.91%

SCL Science Inc. Share Price

Stocks

A246960

KR7246960009

Pharmaceuticals

Valuation: SCL Science Inc.

Chart: SCL Science Inc.

Latest news: SCL Science Inc.

Quotes and Performance

Price Extremes

Managers and Directors: SCL Science Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

1 week	2,475	2,920
1 month	2,130	2,920
Current year	1,389	2,920
1 year	1,389	3,250
3 years	1,389	5,110
5 years	1,389	5,110
10 years	1,300	6,950

Manager	Title	Age	Since
Kyung-Yul Lee CEO	Chief Executive Officer	-	28/12/2022
Se-Yeon Baek CEO	Chief Executive Officer	59	30/09/2024
Dae-Young Kim AUD	Comptroller/Controller/Auditor	63	28/12/2022

Director	Title	Age	Since
Se-Yeon Baek BRD	Director/Board Member	59	30/09/2024
Jeong-Gyun Choi BRD	Director/Board Member	59	30/09/2024
Kyung-Yul Lee BRD	Director/Board Member	-	28/12/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
11/08/25	Chang-ho Jin	Free		12,798	0.0377%
11/08/25	Se-Yeon Baek	Free	Chief Executive Officer	28,500	0.0840%
11/08/25	Han-Jo Kim	Free		1,359	0.0040%	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCL SCIENCE INC.	-6.26%	+7.16%	+2.34%	+23.00%	7.01Cr
ELI LILLY AND COMPANY	+0.22%	+3.11%	+55.54%	+120.46%	1,05600Cr
JOHNSON & JOHNSON	-0.15%	-0.71%	+44.13%	+72.25%	64TCr
ABBVIE INC.	+0.08%	-0.62%	+13.78%	+77.70%	47TCr
MERCK & CO., INC.	-1.68%	-0.93%	+74.80%	+43.06%	37TCr
ROCHE HOLDING AG	-0.06%	-3.88%	+34.32%	+40.74%	34TCr
NOVARTIS AG	-0.79%	+2.01%	+19.82%	+28.48%	28TCr
ASTRAZENECA PLC	-1.19%	-1.21%	+9.82%	+12.15%	25TCr
AMGEN INC.	-0.11%	+4.05%	+49.73%	+58.67%	23TCr
GILEAD SCIENCES, INC.	-0.56%	-0.71%	+35.41%	+102.83%	19TCr
Average	-0.98%	+0.83%	+33.97%	+57.93%	38.16TCr
Weighted average by Cap.	-0.24%	+0.30%	+41.55%	+74.19%

	2024	2025
Net sales	473.71Cr 34.97L 30.8L 29.18L 26.34L 49.65L 34Cr 50.29L 3.49Cr 1.34Cr 17Cr 1.31Cr 1.28Cr 55Cr	2.2TCr 1.62Cr 1.43Cr 1.36Cr 1.22Cr 2.31Cr 155.8Cr 2.34Cr 16Cr 6.24Cr 80Cr 6.1Cr 5.97Cr 255.35Cr
Net income	-373.01Cr -27.54L -24.25L -22.98L -20.74L -39.09L -26Cr -39.6L -2.75Cr -1.06Cr -13Cr -1.03Cr -1.01Cr -43Cr	-393.43Cr -29.04L -25.58L -24.23L -21.88L -41.23L -28Cr -41.77L -2.9Cr -1.12Cr -14Cr -1.09Cr -1.07Cr -46Cr
Net Debt	314.54Cr 23.22L 20.45L 19.37L 17.49L 32.96L 22Cr 33.39L 2.32Cr 89.2L 11Cr 87.19L 85.29L 36Cr	2.25TCr 1.66Cr 1.46Cr 1.39Cr 1.25Cr 2.36Cr 159.5Cr 2.39Cr 17Cr 6.39Cr 82Cr 6.25Cr 6.11Cr 261.41Cr